FIELD: biotechnology.
SUBSTANCE: present invention relates to the field of biotechnology, specifically to the assessment of the therapeutic efficacy of chemotherapy using an antitumor agent, and can be used in medicine.
EFFECT: invention allows to predict the therapeutic efficacy of chemotherapy using an antitumor agent comprising a PI3K/AKT/mTOR inhibitor based on imidazo-oxazine, in a patient suffering from cancer, based on the level of expression of PHLDA1 and/or PIK3C2B in a biological sample taken from the patient.
5 cl, 4 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NOVEL IMIDAZOOXAZINE COMPOUND OR SALT THEREOF | 2012 |
|
RU2578608C2 |
| ANTITUMOR EFFECT AMPLIFYER CONTAINING IMIDAZOOXAAZINE COMPOUND | 2013 |
|
RU2618423C2 |
| METHOD OF TREATING MALIGNANT TUMOUR | 2020 |
|
RU2816126C2 |
| DRUG AND COMPOSITION FOR TREATMENT OF MALIGNANT TUMORS | 2017 |
|
RU2777595C2 |
| COMPOUNDS OF BENZOXAZEPINOXAZOLIDINONES AND METHODS OF USING | 2016 |
|
RU2730529C2 |
| 2-CARBOXAMIDE CYCLOAMINO UREA DERIVATIVES IN COMBINATION WITH HSP90 INHIBITORS FOR TREATING PROLIFERATIVE DISEASES | 2012 |
|
RU2624493C2 |
| SYNERGISTIC COMBINATIONS OF AURISTANE | 2015 |
|
RU2717570C2 |
| BIOMARKERS FOR PREDICTION OF SENSITIVITY TO ANTITUMOR TREATMENT | 2012 |
|
RU2635193C2 |
| MORPHOLINO-SUBSTITUTED DERIVATIVES OF UREA OR CARBAMATE AS MTOR INHIBITORS | 2012 |
|
RU2616619C2 |
| COMBINATIONS OF AKT INHIBITOR COMPOUNDS AND ABIRATERONE, AND APPLICATION METHODS | 2012 |
|
RU2631240C2 |
